Active Pharmaceutical Ingredients CDMO-Global Market Status and Trend Report 2016-2026
Report Summary
Active Pharmaceutical Ingredients CDMO-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on Active Pharmaceutical Ingredients CDMO industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Active Pharmaceutical Ingredients CDMO 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Active Pharmaceutical Ingredients CDMO worldwide, with company and product introduction, position in the Active Pharmaceutical Ingredients CDMO market
Market status and development trend of Active Pharmaceutical Ingredients CDMO by types and applications
Cost and profit status of Active Pharmaceutical Ingredients CDMO, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Active Pharmaceutical Ingredients CDMO market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Active Pharmaceutical Ingredients CDMO industry.
The report segments the global Active Pharmaceutical Ingredients CDMO market as:
Global Active Pharmaceutical Ingredients CDMO Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Active Pharmaceutical Ingredients CDMO Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Antibody Drug Conjugate (ADC)
Others
Global Active Pharmaceutical Ingredients CDMO Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Oncology
Hormonal
Glaucoma
Cardiovascular
Diabetes
Others
Global Active Pharmaceutical Ingredients CDMO Market: Manufacturers Segment Analysis (Company and Product introduction, Active Pharmaceutical Ingredients CDMO Sales Volume, Revenue, Price and Gross Margin):
Cambrex
Recipharm
Thermo Fisher Pantheon
Corden Pharma
Samsung Biologics
Lonza
Catalent
Siegfried
Piramal Pharma Solutions
Boehringer Ingelheim
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Active Pharmaceutical Ingredients CDMO-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on Active Pharmaceutical Ingredients CDMO industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Active Pharmaceutical Ingredients CDMO 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of Active Pharmaceutical Ingredients CDMO worldwide, with company and product introduction, position in the Active Pharmaceutical Ingredients CDMO market
Market status and development trend of Active Pharmaceutical Ingredients CDMO by types and applications
Cost and profit status of Active Pharmaceutical Ingredients CDMO, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Active Pharmaceutical Ingredients CDMO market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Active Pharmaceutical Ingredients CDMO industry.
The report segments the global Active Pharmaceutical Ingredients CDMO market as:
Global Active Pharmaceutical Ingredients CDMO Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Active Pharmaceutical Ingredients CDMO Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Antibody Drug Conjugate (ADC)
Others
Global Active Pharmaceutical Ingredients CDMO Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Oncology
Hormonal
Glaucoma
Cardiovascular
Diabetes
Others
Global Active Pharmaceutical Ingredients CDMO Market: Manufacturers Segment Analysis (Company and Product introduction, Active Pharmaceutical Ingredients CDMO Sales Volume, Revenue, Price and Gross Margin):
Cambrex
Recipharm
Thermo Fisher Pantheon
Corden Pharma
Samsung Biologics
Lonza
Catalent
Siegfried
Piramal Pharma Solutions
Boehringer Ingelheim
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
1.1 Definition of Active Pharmaceutical Ingredients CDMO in This Report
1.2 Commercial Types of Active Pharmaceutical Ingredients CDMO
1.2.1 Traditional Active Pharmaceutical Ingredient (Traditional API)
1.2.2 Highly Potent Active Pharmaceutical Ingredient (HP-API)
1.2.3 Antibody Drug Conjugate (ADC)
1.2.4 Others
1.3 Downstream Application of Active Pharmaceutical Ingredients CDMO
1.3.1 Oncology
1.3.2 Hormonal
1.3.3 Glaucoma
1.3.4 Cardiovascular
1.3.5 Diabetes
1.3.6 Others
1.4 Development History of Active Pharmaceutical Ingredients CDMO
1.5 Market Status and Trend of Active Pharmaceutical Ingredients CDMO 2016-2026
1.5.1 Global Active Pharmaceutical Ingredients CDMO Market Status and Trend 2016-2026
1.5.2 Regional Active Pharmaceutical Ingredients CDMO Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Active Pharmaceutical Ingredients CDMO 2016-2021
2.2 Production Market of Active Pharmaceutical Ingredients CDMO by Regions
2.2.1 Production Volume of Active Pharmaceutical Ingredients CDMO by Regions
2.2.2 Production Value of Active Pharmaceutical Ingredients CDMO by Regions
2.3 Demand Market of Active Pharmaceutical Ingredients CDMO by Regions
2.4 Production and Demand Status of Active Pharmaceutical Ingredients CDMO by Regions
2.4.1 Production and Demand Status of Active Pharmaceutical Ingredients CDMO by Regions 2016-2021
2.4.2 Import and Export Status of Active Pharmaceutical Ingredients CDMO by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Active Pharmaceutical Ingredients CDMO by Types
3.2 Production Value of Active Pharmaceutical Ingredients CDMO by Types
3.3 Market Forecast of Active Pharmaceutical Ingredients CDMO by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Active Pharmaceutical Ingredients CDMO by Downstream Industry
4.2 Market Forecast of Active Pharmaceutical Ingredients CDMO by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
5.1 Global Economy Situation and Trend Overview
5.2 Active Pharmaceutical Ingredients CDMO Downstream Industry Situation and Trend Overview
CHAPTER 6 ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Active Pharmaceutical Ingredients CDMO by Major Manufacturers
6.2 Production Value of Active Pharmaceutical Ingredients CDMO by Major Manufacturers
6.3 Basic Information of Active Pharmaceutical Ingredients CDMO by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Active Pharmaceutical Ingredients CDMO Major Manufacturer
6.3.2 Employees and Revenue Level of Active Pharmaceutical Ingredients CDMO Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Cambrex
7.1.1 Company profile
7.1.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.1.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Cambrex
7.2 Recipharm
7.2.1 Company profile
7.2.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.2.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Recipharm
7.3 Thermo Fisher Pantheon
7.3.1 Company profile
7.3.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.3.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Thermo Fisher Pantheon
7.4 Corden Pharma
7.4.1 Company profile
7.4.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.4.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Corden Pharma
7.5 Samsung Biologics
7.5.1 Company profile
7.5.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.5.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Samsung Biologics
7.6 Lonza
7.6.1 Company profile
7.6.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.6.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Lonza
7.7 Catalent
7.7.1 Company profile
7.7.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.7.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Catalent
7.8 Siegfried
7.8.1 Company profile
7.8.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.8.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Siegfried
7.9 Piramal Pharma Solutions
7.9.1 Company profile
7.9.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.9.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Piramal Pharma Solutions
7.10 Boehringer Ingelheim
7.10.1 Company profile
7.10.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.10.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
8.1 Industry Chain of Active Pharmaceutical Ingredients CDMO
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
9.1 Cost Structure Analysis of Active Pharmaceutical Ingredients CDMO
9.2 Raw Materials Cost Analysis of Active Pharmaceutical Ingredients CDMO
9.3 Labor Cost Analysis of Active Pharmaceutical Ingredients CDMO
9.4 Manufacturing Expenses Analysis of Active Pharmaceutical Ingredients CDMO
CHAPTER 10 MARKETING STATUS ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Active Pharmaceutical Ingredients CDMO in This Report
1.2 Commercial Types of Active Pharmaceutical Ingredients CDMO
1.2.1 Traditional Active Pharmaceutical Ingredient (Traditional API)
1.2.2 Highly Potent Active Pharmaceutical Ingredient (HP-API)
1.2.3 Antibody Drug Conjugate (ADC)
1.2.4 Others
1.3 Downstream Application of Active Pharmaceutical Ingredients CDMO
1.3.1 Oncology
1.3.2 Hormonal
1.3.3 Glaucoma
1.3.4 Cardiovascular
1.3.5 Diabetes
1.3.6 Others
1.4 Development History of Active Pharmaceutical Ingredients CDMO
1.5 Market Status and Trend of Active Pharmaceutical Ingredients CDMO 2016-2026
1.5.1 Global Active Pharmaceutical Ingredients CDMO Market Status and Trend 2016-2026
1.5.2 Regional Active Pharmaceutical Ingredients CDMO Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Active Pharmaceutical Ingredients CDMO 2016-2021
2.2 Production Market of Active Pharmaceutical Ingredients CDMO by Regions
2.2.1 Production Volume of Active Pharmaceutical Ingredients CDMO by Regions
2.2.2 Production Value of Active Pharmaceutical Ingredients CDMO by Regions
2.3 Demand Market of Active Pharmaceutical Ingredients CDMO by Regions
2.4 Production and Demand Status of Active Pharmaceutical Ingredients CDMO by Regions
2.4.1 Production and Demand Status of Active Pharmaceutical Ingredients CDMO by Regions 2016-2021
2.4.2 Import and Export Status of Active Pharmaceutical Ingredients CDMO by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Active Pharmaceutical Ingredients CDMO by Types
3.2 Production Value of Active Pharmaceutical Ingredients CDMO by Types
3.3 Market Forecast of Active Pharmaceutical Ingredients CDMO by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Active Pharmaceutical Ingredients CDMO by Downstream Industry
4.2 Market Forecast of Active Pharmaceutical Ingredients CDMO by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
5.1 Global Economy Situation and Trend Overview
5.2 Active Pharmaceutical Ingredients CDMO Downstream Industry Situation and Trend Overview
CHAPTER 6 ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Active Pharmaceutical Ingredients CDMO by Major Manufacturers
6.2 Production Value of Active Pharmaceutical Ingredients CDMO by Major Manufacturers
6.3 Basic Information of Active Pharmaceutical Ingredients CDMO by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Active Pharmaceutical Ingredients CDMO Major Manufacturer
6.3.2 Employees and Revenue Level of Active Pharmaceutical Ingredients CDMO Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Cambrex
7.1.1 Company profile
7.1.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.1.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Cambrex
7.2 Recipharm
7.2.1 Company profile
7.2.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.2.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Recipharm
7.3 Thermo Fisher Pantheon
7.3.1 Company profile
7.3.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.3.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Thermo Fisher Pantheon
7.4 Corden Pharma
7.4.1 Company profile
7.4.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.4.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Corden Pharma
7.5 Samsung Biologics
7.5.1 Company profile
7.5.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.5.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Samsung Biologics
7.6 Lonza
7.6.1 Company profile
7.6.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.6.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Lonza
7.7 Catalent
7.7.1 Company profile
7.7.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.7.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Catalent
7.8 Siegfried
7.8.1 Company profile
7.8.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.8.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Siegfried
7.9 Piramal Pharma Solutions
7.9.1 Company profile
7.9.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.9.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Piramal Pharma Solutions
7.10 Boehringer Ingelheim
7.10.1 Company profile
7.10.2 Representative Active Pharmaceutical Ingredients CDMO Product
7.10.3 Active Pharmaceutical Ingredients CDMO Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
8.1 Industry Chain of Active Pharmaceutical Ingredients CDMO
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
9.1 Cost Structure Analysis of Active Pharmaceutical Ingredients CDMO
9.2 Raw Materials Cost Analysis of Active Pharmaceutical Ingredients CDMO
9.3 Labor Cost Analysis of Active Pharmaceutical Ingredients CDMO
9.4 Manufacturing Expenses Analysis of Active Pharmaceutical Ingredients CDMO
CHAPTER 10 MARKETING STATUS ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS CDMO
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
